MannKind Corporation Share Price

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
4.23 USD +1.20% Intraday chart for MannKind Corporation +1.20% +16.21%
Sales 2024 * 260M 20.81B Sales 2025 * 313M 25.04B Capitalization 1.15B 91.69B
Net income 2024 * 38M 3.04B Net income 2025 * 73M 5.84B EV / Sales 2024 * 3.45 x
Net cash position 2024 * 248M 19.88B Net cash position 2025 * 273M 21.83B EV / Sales 2025 * 2.79 x
P/E ratio 2024 *
32 x
P/E ratio 2025 *
18.5 x
Employees 413
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.47%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.20%
1 week+1.20%
Current month-6.62%
1 month-13.85%
3 months+26.27%
6 months+4.70%
Current year+16.21%
More quotes
1 week
4.06
Extreme 4.06
4.37
1 month
3.97
Extreme 3.97
4.74
Current year
3.17
Extreme 3.17
5.40
1 year
3.17
Extreme 3.17
5.75
3 years
2.49
Extreme 2.49
5.75
5 years
0.80
Extreme 0.8
6.25
10 years
0.67
Extreme 0.6662
57.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 13/03/16
Chief Tech/Sci/R&D Officer 57 30/09/22
Chief Tech/Sci/R&D Officer - 30/08/20
Members of the board TitleAgeSince
Director/Board Member 55 26/11/18
Director/Board Member 69 31/12/19
Director/Board Member 80 30/09/03
More insiders
Date Price Change Volume
26/04/24 4.23 +1.20% 2,165,307
25/04/24 4.18 -0.24% 1,775,464
24/04/24 4.19 +0.72% 2,219,014
23/04/24 4.16 +1.22% 1,020,715
22/04/24 4.11 -1.67% 1,754,699

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.23 USD
Average target price
7.083 USD
Spread / Average Target
+67.45%
Consensus